Precision BioSciences Inc. has entered into an underwriting agreement to raise approximately $116.5 million through the issuance of common stock and pre-funded warrants. This significant capital raise is designed to fund the company’s ongoing research and development efforts, particularly for its PBGENE-HBV and PBGENE-DMD projects. The agreement was made with TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives of the underwriters.

The offering consists of 10,235,077 shares of common stock priced at $7.75 per share, along with pre-funded warrants for an additional 5,893,964 shares. The pre-funded warrants are priced at $7.749995 each, reflecting the exercise price of $0.000005 per share. The net proceeds from this offering will be allocated towards advancing Precision BioSciences’ research initiatives and general corporate purposes.

About Precision BioSciences Inc.

Precision BioSciences Inc., incorporated in Delaware, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company trades under the ticker symbol DTIL on the Nasdaq exchange. As a smaller reporting company, it has been actively engaging in various financing activities to support its growth and development in the competitive biotechnology landscape.

Details from the Filing

The SEC filing dated November 6, 2026, outlines the specifics of the underwriting agreement. The company anticipates that the closing of the offering will occur on November 6, 2026, subject to customary closing conditions. The filing indicates, "The Company intends to use the net proceeds of the Offering to fund the continued research and development of PBGENE-HBV and PBGENE-DMD, and for working capital and general corporate purposes." The underwriting agreement includes standard representations and warranties, as well as indemnification obligations.

Impact on the Industry

This capital raise is expected to enhance Precision BioSciences' financial stability and capacity for innovation, potentially influencing its competitive position within the biological products industry. Other companies in this sector may need to evaluate their own funding strategies in light of this development, as Precision BioSciences aims to leverage this funding for significant advancements in gene therapy.

What's Next?

The filing does not specify what happens next beyond the anticipated closing of the offering. However, the company is likely to focus on utilizing the raised funds effectively to advance its research projects.